Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.36 |
| ▸ | CCR8 | P51685 | 2/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12463791 | 0.82 | KDM4E (0.47) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL12134726 | 0.82 | PSMB5 (0.41) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL12463810 | 0.80 | PPARG (0.44) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL22792556 | 0.78 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL5857446 | 0.78 | PDE4A (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL9385457 | 0.77 | CCR1 (0.48) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL9953697 | 0.77 | DHODH (0.45) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL30724619 | 0.77 | DHODH (0.45) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL17683804 | 0.75 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL3893117 | 0.74 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778306-B | Synthesis method of 1, 8-naphthyridine derivative | 吉林化工学院 | 2024-01-26 | — | — | CN | disclosed |
| CN-112778306-A | Synthetic method of 1, 8-naphthyridine derivative | 吉林化工学院 | 2021-05-11 | — | — | CN | disclosed |
| WO-2015095430-A1 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF MACROLACTAMS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-7879863-B2 | Kallikrein inhibitors such as N-((2R)-3-methyl-2-{[4-(trifluoromethyl)phenyl]amino}butyl)-2-phenylacetamide trifluoroacetate, used for the treatment of gastrointestinal disorders, periodontal diseases, skin disorders, arthritis, hypotension, edema, respiratory system disorders and proliferative diseases | AJINOMOTO CO., INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | ALDH1A1 2674/4885MEN1 761/4885KMT2A 2604/4885 |
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | ALDH1A1 747/4885MEN1 980/4885KMT2A 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.